Monitoring Therapeutic Responses to Silicified Cancer Cell Immunotherapy Using PET/MRI in a Mouse Model of Disseminated Ovarian Cancer

Current imaging approaches used to monitor tumor progression can lack the ability to distinguish true progression from pseudoprogression. Simultaneous metabolic 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) offers new opportunities...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-09, Vol.23 (18), p.10525
Main Authors: Taylor, Erik N., Wilson, Colin M., Franco, Stefan, De May, Henning, Medina, Lorél Y., Yang, Yirong, Flores, Erica B., Bartee, Eric, Selwyn, Reed G., Serda, Rita E.
Format: Article
Language:English
Subjects:
Abdomen
Ascites
Bioluminescence
Body fat
Cancer immunotherapy
Cancer vaccines
Flow cytometry
Fluorine isotopes
Glucose
Histopathology
Immune system
Immunotherapy
Ligands
Longitudinal studies
Lymphocytes
Magnetic resonance imaging
Medical imaging
Mesentery
Metastasis
Monitoring
Ovarian cancer
Positron emission
Positron emission tomography
Telemedicine
Tomography
Tumor cells
Tumor microenvironment
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current imaging approaches used to monitor tumor progression can lack the ability to distinguish true progression from pseudoprogression. Simultaneous metabolic 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) offers new opportunities to overcome this challenge by refining tumor identification and monitoring therapeutic responses to cancer immunotherapy. In the current work, spatial and quantitative analysis of tumor burden were performed using simultaneous [18F]FDG-PET/MRI to monitor therapeutic responses to a novel silicified cancer cell immunotherapy in a mouse model of disseminated serous epithelial ovarian cancer. Tumor progression was validated by bioluminescence imaging of luciferase expressing tumor cells, flow cytometric analysis of immune cells in the tumor microenvironment, and histopathology. While PET demonstrated the presence of metabolically active cancer cells through [18F]FDG uptake, MRI confirmed cancer-related accumulation of ascites and tissue anatomy. This approach provides complementary information on disease status without a confounding signal from treatment-induced inflammation. This work provides a possible roadmap to facilitate accurate monitoring of therapeutic responses to cancer immunotherapies.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms231810525